FULC
Fulcrum Therapeutics, Inc. Healthcare Biotechnology
6/12
Innovation Score
Red Flags (1)
HYPE_PRICING ($0.0M rev, $297M mcap)
Patent Activity
1/3
2 patents found
OK_NORMALIZED
Cash Runway
3/3
58 months of cash remaining based on current burn rate.
Cash on hand: $318.8M
Cash on hand: $318.8M
Revenue Trajectory
1/3
Revenue: $0.0M
Revenue growth data unavailable.
Revenue growth data unavailable.
Management Quality
1/3
Insider ownership: 32.3%
SBC/Revenue: 0.0%
No reverse splits detected
SBC/Revenue: 0.0%
No reverse splits detected
Key Metrics
Market Cap
$296.8M
Revenue
$0.0M
Revenue Growth (YoY)
N/A
Cash on Hand
$318.8M
Cash Runway
58 months
Shares Outstanding
76.3M
Insider Ownership
32.3%
SBC / Revenue
0.0%
Sector / Industry
Healthcare / Biotechnology
Patents (2)
Match type: OK_NORMALIZED
- Compositions and methods for modulating FMR1 expression
- Macrocyclic azolopyridine derivatives as EED and PRC2 modulators
7-Step Risk Assessment
How FULC maps to our micro cap methodology:
- Innovation Signal 2 patents identified. This suggests the company is investing in defensible IP.
- Cash Runway Check 58 months of runway. Comfortable buffer for execution.
- Revenue Trajectory Revenue data unavailable.
- Management Alignment Insiders hold 32.3% of shares. SBC is 0.0% of revenue.
- Competitive Moat Review the company's 10-K for barriers to entry: patents, network effects, switching costs, regulatory approvals. This step requires manual research.
- Catalyst Identification Look for upcoming catalysts: FDA decisions, contract wins, product launches, partnerships. Check recent 8-K filings and earnings transcripts.
- Position Sizing Micro caps carry outsized risk. Consider position sizing relative to conviction level and portfolio concentration. This is a $296.8M company.
Financial Detail
Free Cash Flow
$-37.4M
FCF Yield
-12.6%
Return on Equity
-32.4%
Debt / Equity
1.7%
Gross Margin
N/A
Profit Margin
N/A
Operating Margin
N/A
Price / Book
0.96
Current Ratio
31.35
Dividend Yield
None
Share Count Change (YoY)
N/A
Share Count Change (3yr)
N/A
Quality Flags
Low Debt
Free Cash Flow Trend
Insufficient Data
Consecutive Years FCF Positive
0
Disclaimer: This is an automated screening tool, not investment advice. Micro cap stocks are inherently risky with low liquidity and high volatility. The innovation score is based on publicly available data and may not reflect the full picture. Steps 5-7 of the methodology require your own research. See our full disclaimer.
Last screened: 2026-08-08